CLINICAL TRIALS PROFILE FOR DACTINOMYCIN

All Clinical Trials for DACTINOMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002610 ↗	Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors	Completed	National Cancer Institute (NCI)	Phase 3	1996-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00002516 ↗	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	Medical Research Council	Phase 3	1992-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma. PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
NCT00002516 ↗	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	University Hospital Muenster	Phase 3	1992-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma. PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
NCT00002489 ↗	Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1991-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have non-testicular malignant germ cell tumors.

Clinical Trial Conditions for DACTINOMYCIN

Condition Name

Condition Name for DACTINOMYCIN
Intervention	Trials
Sarcoma	13
Kidney Cancer	5
Rhabdomyosarcoma	5
Adult Rhabdomyosarcoma	4

Condition MeSH

Condition MeSH for DACTINOMYCIN
Intervention	Trials
Rhabdomyosarcoma	18
Sarcoma	16
Wilms Tumor	10
Rhabdomyosarcoma, Embryonal	7

Clinical Trial Locations for DACTINOMYCIN

Trials by Country

+

−

Trials by Country for DACTINOMYCIN
Location	Trials
United States	766
Canada	122
Australia	66
Japan	49
New Zealand	19

Trials by US State

+

−

Trials by US State for DACTINOMYCIN
Location	Trials
Texas	22
California	22
New York	22
Pennsylvania	20
Ohio	20

Clinical Trial Progress for DACTINOMYCIN

Clinical Trial Phase

Clinical Trial Phase for DACTINOMYCIN
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	26
Phase 2	15

Clinical Trial Status

Clinical Trial Status for DACTINOMYCIN
Clinical Trial Phase	Trials
Completed	18
Unknown status	11
Active, not recruiting	6

Clinical Trial Sponsors for DACTINOMYCIN

Sponsor Name

Sponsor Name for DACTINOMYCIN
Sponsor	Trials
National Cancer Institute (NCI)	24
Children's Oncology Group	16
Children's Cancer and Leukaemia Group	5

Sponsor Type

Sponsor Type for DACTINOMYCIN
Sponsor	Trials
Other	65
NIH	24
Industry	2

Dactinomycin: Clinical Trials, Market Analysis, and Projections

Introduction to Dactinomycin

Dactinomycin, also known as Actinomycin D, is a potent chemotherapeutic agent used primarily in the treatment of various cancers, including Wilms' tumor, rhabdomyosarcoma, and certain types of testicular cancers. Here, we will delve into the current clinical trials, market analysis, and future projections for this crucial drug.

Clinical Trials Update

Wilms' Tumor Trials

One significant clinical trial involving dactinomycin is the phase III trial conducted by UCSF, which focuses on treating younger patients with newly diagnosed stage I, II, or III Wilms' tumor. This trial evaluates the efficacy of vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only. The primary objectives include assessing the overall and event-free survival of patients, particularly those with favorable histology Wilms' tumor. Patients undergo a regimen that includes nephrectomy followed by chemotherapy and possibly radiotherapy, with dactinomycin administered intravenously in alternating cycles with doxorubicin[1].

Rhabdomyosarcoma Trials

Another notable trial is the randomized phase III study comparing combination chemotherapy with or without temsirolimus in treating patients with rhabdomyosarcoma. This trial involves dactinomycin as part of the chemotherapy regimen, which also includes vincristine, cyclophosphamide, and irinotecan. The study aims to evaluate the efficacy of adding temsirolimus to the standard chemotherapy regimen and to assess various outcomes based on FDG-PET response and circulating tumor DNA[4].

Market Analysis

Market Size and Forecast

The dactinomycin market is projected to grow significantly over the next few years. As of 2023, the market size was valued at USD 6.9 billion and is expected to reach USD 7.81 billion by 2031, growing at a CAGR of 8.27% during the forecast period of 2024-2030[2].

Key Drivers

Several factors are driving the growth of the dactinomycin market:

• Rising Incidence of Cancers: The increasing global incidence of cancers, such as Wilms' tumor and rhabdomyosarcoma, is driving the demand for effective cancer treatments, including dactinomycin[2].
• Advancements in Cancer Treatment Protocols: Ongoing research and clinical trials are exploring new applications and combinations of dactinomycin with other therapies, which is expected to increase its usage in oncology treatment protocols[2].
• Aging Population: The growing and aging population is leading to an increase in cancer diagnoses, thereby boosting the demand for dactinomycin[2].
• Increased R&D Investment: Pharmaceutical companies are investing heavily in research and development for innovative cancer therapies, including those involving dactinomycin[2].

Market Segmentation

The dactinomycin market is segmented by end users, with hospitals and cancer treatment centers being the primary segments. These settings have the necessary infrastructure and experienced professionals to administer and monitor dactinomycin treatment effectively[2].

Geographic Analysis

Geographically, the dactinomycin market is prominent in North America and Europe, due to advanced healthcare infrastructure and extensive research activities. The Asia-Pacific region is also witnessing rapid growth, driven by a large patient population and improving healthcare facilities[2].

Market Projections

Growth Prospects

The market for dactinomycin is expected to continue growing due to several favorable factors:

• Availability of Generic Versions: The entry of generic versions of dactinomycin is making it more accessible and affordable, leading to increased use in various healthcare settings[2].
• Healthcare Infrastructure Improvement: Enhancements in healthcare infrastructure in developing regions are facilitating better access to cancer treatments, including dactinomycin[2].
• Supportive Government Policies: Governments are increasingly supporting cancer research and treatment initiatives, which includes improving access to existing cancer therapies like dactinomycin[2].

Challenges

Despite the positive outlook, there are several challenges that could impact the market:

• Regulatory Challenges: The approval process for new drugs or generics can be lengthy and complicated, potentially delaying market entry and affecting supply[2].
• High Development Costs: The costs associated with research, development, and clinical trials can be substantial, which may deter companies from investing heavily in dactinomycin[2].
• Competition from Other Therapies: The cancer treatment market is highly competitive, with newer therapies and treatment modalities potentially offering better efficacy or fewer side effects, which could reduce the demand for dactinomycin[2].

Key Takeaways

• Clinical Trials: Ongoing clinical trials are evaluating the efficacy of dactinomycin in treating Wilms' tumor and rhabdomyosarcoma, with a focus on optimizing treatment protocols.
• Market Growth: The dactinomycin market is projected to grow at a CAGR of 8.27% from 2024 to 2030, driven by increasing cancer incidence and advancements in treatment protocols.
• Market Segmentation: The market is segmented by end users, with hospitals and cancer treatment centers being key segments, and geographically, with North America, Europe, and the Asia-Pacific region showing significant growth.
• Challenges: Regulatory challenges, high development costs, and competition from other therapies are potential hurdles that could impact market growth.

FAQs

What is dactinomycin primarily used for?

Dactinomycin is primarily used in the treatment of various cancers, including Wilms' tumor, rhabdomyosarcoma, and certain types of testicular cancers.

What are the key drivers of the dactinomycin market?

The key drivers include the rising incidence of cancers, advancements in cancer treatment protocols, an aging population, and increased R&D investment.

What are the primary segments of the dactinomycin market?

The primary segments are hospitals and cancer treatment centers, which play a critical role in the administration and research applications of dactinomycin.

What are the projected growth rates for the dactinomycin market?

The market is expected to grow at a CAGR of 8.27% from 2024 to 2030.

What challenges might impact the dactinomycin market?

Regulatory challenges, high development costs, and competition from other therapies are potential challenges that could impact market growth.

Sources

1. UCSF Clinical Trials: "Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor."
2. Verified Market Research: "Dactinomycin Market Size, Share, Scope, Trends And Forecast."
3. The Business Research Company: "Dactinomycin Market Report 2024."
4. ClinicalTrials.gov: "Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Rhabdomyosarcoma."
5. Market.us: "Nephroblastoma Treatment Market Size Analysis | CAGR of 7.8%."